サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1551649

肝細胞がん治療薬の世界市場

Hepatocellular Carcinoma Drugs

出版日
ページ情報
英文 198 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
肝細胞がん治療薬の世界市場
出版日: 2024年09月10日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 198 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肝細胞がん治療薬の世界市場は2030年までに17億米ドルに達する見込み

2023年に11億米ドルと推定される肝細胞がん治療薬の世界市場は、分析期間2023-2030年にCAGR 6.1％で成長し、2030年には17億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである化学療法治療は、CAGR 7.2％を記録し、分析期間終了時には6億6,480万米ドルに達すると予測されます。ブラキセラピー治療分野の成長率は、分析期間でCAGR 6.2％と推定されます。

米国市場は推定2億9,740万米ドル、中国はCAGR10.1％で成長予測

米国の肝細胞がん治療薬市場は、2023年に2億9,740万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに3億5,860万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは10.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5%と6.2%と予測されています。欧州では、ドイツがCAGR 3.8%で成長すると予測されています。

世界の肝細胞がん治療薬市場- 主要動向と促進要因まとめ

肝細胞がん治療薬の最新動向は？

原発性肝がんの中で最も一般的なタイプである肝細胞がん（HCC）は、ここ数年で薬剤開発が大きく進展し、患者に新たな希望をもたらしています。肝細胞がんに対する従来の治療選択肢は、手術、肝移植、ラジオ波焼灼療法や経動脈的化学塞栓療法のような局所療法にほぼ限られていました。しかし、分子標的治療薬や免疫療法の登場により、治療の状況は一変しました。FDAが初めて承認した肝細胞がんの標的治療薬であるソラフェニブは、腫瘍細胞の増殖と血管新生を阻害することで転機をもたらしました。それ以来、レンバチニブ、レゴラフェニブ、カボザンチニブなどの新しい薬剤が登場し、生存利益と忍容性が改善されました。さらに、ニボルマブやペムブロリズマブなどの免疫チェックポイント阻害剤のイントロダクションより、特に手術の適応がない患者や進行期の患者に対する治療の選択肢がさらに広がった。これらの治療薬は、がん細胞に対する身体の免疫反応を増強することによって作用し、従来のアプローチを補完する新しい作用機序を提供します。肝細胞がん治療薬の絶え間ない進化は、患者の予後を改善するための継続的な調査と臨床試験の重要性を強調しています。

併用療法は肝細胞がんの治療パラダイムをどのように変えているのか？

単剤治療ではしばしば有効性と持続性に限界があるとの認識から、併用療法が肝細胞がん治療の基礎となりつつあります。標的療法と免疫療法の併用は、特にこれまで選択肢が限られていた進行期において有望な結果を示しています。例えば、免疫チェックポイント阻害薬であるアテゾリズマブと抗VEGF抗体であるベバシズマブの併用療法は、ソラフェニブと比較して優れた有効性を示し、切除不能肝細胞がんの一次治療における新たな標準治療となった。この併用療法は、免疫調節と血管新生阻害の相乗効果を利用し、生存期間の延長と病勢進行の抑制につながります。同様に、現在進行中の臨床試験では、二重チェックポイント阻害薬（例えば、ニボルマブとイピリムマブの併用）や、免疫チェックポイント阻害薬と並行してチロシンキナーゼ阻害薬を使用するなど、様々な併用療法が検討されています。これらの併用戦略の成功は、特にHCCのように複雑で不均一な疾患において、耐性メカニズムを克服し、より持続的な奏効を達成する可能性を強調しています。研究が進むにつれて、併用療法は治療状況をさらに変化させ、HCC患者により個別化された効果的な治療選択肢を提供することになると思われます。

肝細胞がん治療薬の開発における課題と機会とは？

肝細胞がん治療薬の開発はいくつかの課題に直面しているが、同時に革新と進歩のための大きなチャンスでもあります。主な課題のひとつは、疾患の不均一性です。肝細胞がんは、B型肝炎やC型肝炎の感染、非アルコール性脂肪性肝炎（NASH）、肝硬変など、さまざまな肝臓の基礎疾患から生じる可能性があり、それぞれ治療に対する反応が異なります。このような多様性により、画一的な治療法の開発は困難であり、より個別化された治療アプローチが必要となります。さらに、肝細胞がん患者は肝機能が低下していることが多いため、薬物代謝における肝臓の中心的役割は、有効かつ安全な治療法を開発する上でさらなる課題となります。このような課題にもかかわらず、特にバイオマーカー探索と精密医療の分野では、技術革新の大きなチャンスがあります。治療に対する反応を予測する分子マーカーを同定することで、より的を絞った治療アプローチが可能になり、有効性の向上と副作用の最小化が期待できます。さらに、腸肝軸を利用し、肝細胞がんの進行におけるマイクロバイオームの役割を探求することへの関心が高まっており、治療介入の新たな道を提示しています。これらの課題と機会は、ゲノム学、免疫学、薬理学の進歩を統合した、HCC治療薬開発への学際的アプローチの必要性を強調しています。

肝細胞がん治療薬市場の成長の原動力は？

肝細胞がん治療薬市場の成長は、医療技術の進歩、ヘルスケアプラクティスのシフト、患者層の変化を反映したいくつかの要因によってもたらされます。主な要因の一つは、C型肝炎、B型肝炎、非アルコール性脂肪性肝疾患（NAFLD）などの慢性肝疾患の罹患率の上昇に後押しされた、世界の肝細胞がんの発生率の増加です。このような患者数の増加により、効果的な治療オプションに対する需要が高まっています。加えて、バイオテクノロジーの急速な進歩と新規ドラッグデリバリーシステムの開発により、より的を絞った個別化治療の創出が可能になり、肝細胞がん治療の効果を高め、副作用を軽減することができるようになった。医薬品開発における人工知能（AI）と機械学習の統合も、新たな治療候補の発見と臨床試験デザインの最適化を加速し、新薬の市場投入までの時間を短縮しています。さらに、早期発見・早期治療のメリットに対する患者やヘルスケア提供者の意識の高まりが、先進治療の採用を後押ししています。ヘルスケア・インフラを改善し、革新的な治療法へのアクセスを向上させる国が増えるにつれて、肝細胞がん治療薬の需要は拡大すると予想されます。このような要因が、薬剤開拓における継続的な技術革新と相まって、肝細胞がん治療薬市場の拡大を後押ししています。

調査対象企業の例（注目の51社）

  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche AG
  • Hepion Pharmaceuticals
  • ImmunoPhotonics
  • Imvax
  • Merck & Co., Inc.
  • Novartis AG
  • RayzeBio
  • SillaJen Biotherapeutics
  • TriSalus Life Sciences
  • Blepharitis Drugs

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26732

Global Hepatocellular Carcinoma Drugs Market to Reach US$1.7 Billion by 2030

The global market for Hepatocellular Carcinoma Drugs estimated at US$1.1 Billion in the year 2023, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 6.1% over the analysis period 2023-2030. Chemotherapy Treatment, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$664.8 Million by the end of the analysis period. Growth in the Brachytherapy Treatment segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$297.4 Million While China is Forecast to Grow at 10.1% CAGR

The Hepatocellular Carcinoma Drugs market in the U.S. is estimated at US$297.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$358.6 Million by the year 2030 trailing a CAGR of 10.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Hepatocellular Carcinoma Drugs Market - Key Trends and Drivers Summarized

What Are the Latest Developments in Hepatocellular Carcinoma Drugs?

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, has seen significant advancements in drug development over recent years, offering new hope to patients. Traditional treatment options for HCC were largely limited to surgery, liver transplantation, and localized therapies like radiofrequency ablation or transarterial chemoembolization. However, the advent of targeted therapies and immunotherapies has revolutionized the treatment landscape. Sorafenib, the first FDA-approved targeted therapy for HCC, marked a turning point by inhibiting tumor cell proliferation and angiogenesis. Since then, newer agents like lenvatinib, regorafenib, and cabozantinib have emerged, offering improved survival benefits and tolerability. In addition, the introduction of immune checkpoint inhibitors, such as nivolumab and pembrolizumab, has further expanded treatment options, particularly for patients who are not candidates for surgery or who have advanced-stage disease. These therapies work by enhancing the body's immune response against cancer cells, offering a novel mechanism of action that complements traditional approaches. The continuous evolution of HCC drug therapies underscores the importance of ongoing research and clinical trials in improving patient outcomes.

How Are Combination Therapies Changing the Treatment Paradigm for HCC?

Combination therapies are increasingly becoming the cornerstone of HCC treatment, driven by the recognition that single-agent therapies often face limitations in efficacy and durability. Combining targeted therapies with immunotherapies has shown promising results, particularly in advanced stages of the disease where options were previously limited. For example, the combination of atezolizumab, an immune checkpoint inhibitor, with bevacizumab, an anti-VEGF antibody, has demonstrated superior efficacy compared to sorafenib, setting a new standard of care in first-line treatment for unresectable HCC. This combination exploits the synergistic effects of immune modulation and angiogenesis inhibition, leading to prolonged survival and better control of disease progression. Similarly, ongoing clinical trials are exploring various other combinations, including dual checkpoint inhibition (e.g., nivolumab with ipilimumab) and the use of tyrosine kinase inhibitors alongside immune checkpoint inhibitors. The success of these combination strategies highlights the potential to overcome resistance mechanisms and achieve more durable responses, particularly in a disease as complex and heterogeneous as HCC. As research continues, combination therapies are likely to further reshape the therapeutic landscape, offering more personalized and effective treatment options for HCC patients.

What Are the Challenges and Opportunities in Developing HCC Drugs?

The development of drugs for HCC faces several challenges, yet it also presents significant opportunities for innovation and advancement. One of the primary challenges is the heterogeneity of the disease, as HCC can arise from various underlying liver conditions, such as hepatitis B or C infection, non-alcoholic steatohepatitis (NASH), or cirrhosis, each of which may respond differently to treatment. This diversity makes it difficult to develop a one-size-fits-all therapy and necessitates a more personalized approach to treatment. Moreover, the liver's central role in drug metabolism poses additional challenges in developing therapies that are both effective and safe, as patients with HCC often have compromised liver function. Despite these challenges, there are significant opportunities for innovation, particularly in the areas of biomarker discovery and precision medicine. Identifying molecular markers that predict response to therapy could enable more targeted treatment approaches, improving efficacy and minimizing side effects. Additionally, the growing interest in harnessing the gut-liver axis and exploring the role of the microbiome in HCC progression presents new avenues for therapeutic intervention. These challenges and opportunities underscore the need for a multidisciplinary approach to HCC drug development, integrating advances in genomics, immunology, and pharmacology.

What Is Driving Growth in the Hepatocellular Carcinoma Drugs Market?

The growth in the hepatocellular carcinoma drugs market is driven by several factors that reflect advancements in medical technology, shifts in healthcare practices, and changing patient demographics. One of the primary drivers is the increasing incidence of HCC globally, fueled by rising rates of chronic liver diseases such as hepatitis C, hepatitis B, and non-alcoholic fatty liver disease (NAFLD). This growing patient population has heightened the demand for effective treatment options. Additionally, the rapid advancement in biotechnology and the development of novel drug delivery systems have enabled the creation of more targeted and personalized therapies, enhancing the effectiveness and reducing the side effects of HCC treatments. The integration of artificial intelligence (AI) and machine learning in drug development is also accelerating the discovery of new therapeutic candidates and optimizing clinical trial designs, thereby shortening the time to market for new drugs. Furthermore, increasing awareness among patients and healthcare providers about the benefits of early detection and treatment is driving the adoption of advanced therapies. As more countries improve their healthcare infrastructure and increase access to innovative treatments, the demand for HCC drugs is expected to grow. These factors, combined with the ongoing innovation in drug development, are propelling the expansion of the hepatocellular carcinoma drugs market.

Select Competitors (Total 51 Featured) -

  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche AG
  • Hepion Pharmaceuticals
  • ImmunoPhotonics
  • Imvax
  • Merck & Co., Inc.
  • Novartis AG
  • RayzeBio
  • SillaJen Biotherapeutics
  • TriSalus Life Sciences
  • Blepharitis Drugs

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Hepatocellular Carcinoma Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Liver Cancer Expands Addressable Market Opportunity for Hepatocellular Carcinoma Drugs
    • Advancements in Targeted Therapies Propel Growth in Precision Medicine for Hepatocellular Carcinoma
    • Increasing Adoption of Immunotherapy Strengthens Business Case for Novel Hepatocellular Carcinoma Treatments
    • Growing Focus on Combination Therapies Spurs Growth in Multi-Modal Treatment Approaches
    • Emergence of Biomarker-Based Therapies Throws the Spotlight on Personalized Hepatocellular Carcinoma Drug Development
    • Challenges in Drug Resistance and Recurrence Present Opportunities for Innovation in Next-Generation Therapies
    • Expansion of Clinical Trials and Research Initiatives Creates New Pathways for Hepatocellular Carcinoma Drug Approvals
    • Increasing Prevalence of Risk Factors Such as Hepatitis and Cirrhosis Expands the Market for Preventive and Therapeutic Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hepatocellular Carcinoma Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hepatocellular Carcinoma Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Hepatocellular Carcinoma Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Brachytherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Brachytherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Brachytherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Local Ablation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Local Ablation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Local Ablation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Japan 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • CHINA
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: China 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Hepatocellular Carcinoma Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Hepatocellular Carcinoma Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: France 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Germany 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Italy 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: UK 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Spain 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Russia 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Rest of Europe 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Hepatocellular Carcinoma Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Hepatocellular Carcinoma Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 65: Australia Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Australia Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Australia 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • INDIA
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 68: India Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: India Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: India 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 71: South Korea Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: South Korea Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: South Korea 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Rest of Asia-Pacific Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Hepatocellular Carcinoma Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Hepatocellular Carcinoma Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 83: Argentina Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Argentina Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Argentina 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 86: Brazil Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Brazil Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Brazil 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 89: Mexico Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Mexico Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Mexico 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Latin America Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Latin America 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Hepatocellular Carcinoma Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Hepatocellular Carcinoma Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 101: Iran Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Iran Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Iran 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 104: Israel Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Israel Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Israel 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Saudi Arabia Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Saudi Arabia 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 110: UAE Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UAE Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: UAE 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of Middle East Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of Middle East 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030
  • AFRICA
    • Hepatocellular Carcinoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 116: Africa Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Africa Historic Review for Hepatocellular Carcinoma Drugs by Treatment Type - Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Africa 16-Year Perspective for Hepatocellular Carcinoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery and Other Treatment Types for the Years 2014, 2024 & 2030

IV. COMPETITION